Revolutionary Approach

Xeltis is revolutionizing the treatment of heart valve disease. In a process called Endogenous Tissue Restoration (ETR), the patient’s natural healing system develops tissue that pervades Xeltis’ implant, forming a new, natural and fully functional heart valve. As ETR occurs, Xeltis’ heart valves are gradually absorbed by the body.

Xeltis is leveraging breakthrough science to transform heart valve treatment – making the seemingly impossible, possible.

Xeltis’ heart valves have a porous structure made of polymers, based on Nobel-prize awarded science.

The latest generation of supramolecular polymers are strong and flexible enough to meet the requirements of a beating heart.

Xeltis’ history is the culmination of substantial developments in regenerative medicine, supramolecular chemistry and electrospinning.



First tissue transplantation experiments


cardiovascular restoration

First cultivation of cells outside of the body and organ ‘culture’ by Alexis Carrel – Nobel Prize laureate for his transplantation work


cardiovascular restoration

First bioreactor created by unique engineering medicine cooperation: Carell and world-famous pilot Charles A. Lindbergh

1960s – 80s:

Fundamental in vitro tissue growth work with first dermal cell culture on a scaffold from Massachusetts General Hospital and Boston MIT collaboration



Tissue engineering: mouse with subcutaneous artificial scaffold works as bioreactor for cell in-growth. Harvard at the center of the heart-valve tissue-engineering



Cardiovascular tissue engineering takes off with University of Zurich (UZH) collaborating with Frank Baaijens’ team at Eindhoven University of Technology (TU/e)

2006 and 2007:

cardiovascular restoration

Xeltis and QTIS founded respectively as spin-offs of UZH and TU/e to develop tissue-engineered heart valves




Supramolecular chemistry postulates


1960s – 80s:

cardiovascular restoration

Fundamental science of supramolecular chemistry established with 1987 Nobel Prize for Chemistry awarded to Jean-Marie Lehn, Donald J. Cram and Charles J. Pedersen for their supramolecular chemistry work


cardiovascular restoration

New supramolecular building blocks’ development by Bert Meijer at Eindhoven University of Technology



First electrospinning experiments

cardiovascular restoration


Electrospinning first patented


First industrial use of electrospun equipment

1940s – 60s:

Industrial production of electrospun filters



Growth of scientific research on electrospinning



Research develops on usage of electrospinning in medical applications



Research on tissue regeneration, supramolecular polymers and electrospinning join with Frank Baaijens’ group starting research on ‘in situ tissue engineering’, now called ETR.

cardiovascular restoration


Xeltis and QTIS merge, abandon tissue engineering to focus on ETR and to develop the RestoreX technology platform.


First patients implanted with Xeltis bioabsorbable blood vessels (pulmonary conduit) and patches.


First patient implanted with Xeltis bioabsorbable pulmonary heart valve in clinical trials, with Thierry Carrel as Principal Investigator.

cardiovascular restoration

Xeltis International Medical and Scientific Advisory Boards established.

Xeltis bioabsorbable aortic valve in preclinical trials


Xeltis is carrying the legacy of hundreds of years of research made by incredible visionaries and scientists.

Most of the (contemporary) people named are today involved with the company.

Scientific Literature

  1. The Journal of Thoracic and Cardiovascular Surgery (JTCVS): Total Cavo-Pulmonary Connection with a New Bio-Absorbable Vascular Graft First Clinical Experience VIEW PDF
  2. Biomaterials: In Situ Heart Valve Tissue Engineering Using a Bioresorbable Elastomeric Implant – From Material Design to 12 Months Follow-up in Sheep VIEW PDF
  3. Science Translational Medicine: 50 Shades of Red VIEW PDF
  4. EuroIntervention Restorative valve therapy by endogenous tissue restoration: tomorrow's world? VIEW PDF

Academic Partnerships

Xeltis is actively involved in research collaborations with leading academic partners. Scientific research projects enable Xeltis to increase our knowledge of ETR, by leveraging the deep scientific understanding achieved at an academic level, and to contribute to our robust knowledge of technology application in the field.

Xeltis Academic Partnerships include among others:

  • RegMed XB:

    The RegMed XB Institute brings together multiple health foundations, leading scientists, entrepreneurs and government institutions to cooperatively tackle ambitious challenges in regenerative medicine.

  • ImaValve:

    The ImaValve Consortium, led by Professor Bouten from Eindhoven University of Technology (TU/e), aims at using intelligent materials to develop innovative solutions for the challenging research field of in situ cardiovascular restoration. The ImaValve is made of a slowly degrading elastomeric polymer that can be inserted with minimally invasive surgery.

  • iValve-II:

    The iValve-II project is a continuation from the BMM iValve project, with a public-private consortium led by Professor Bouten from TU/e. The focus of this academic collaboration is on using restorative approaches to repair or replace damaged tissues and organs.

  • InSiteVx:

    The InSiTeVx Consortium, led by Professor Dankers from TU/e, is investigating whether the understanding on cardiovascular restoration from previous projects can be translated to develop an off-the-shelf, synthetic, biodegradable vascular access graft for dialysis.